Multiple Sclerosis Therapeutics Market to Grow at a CAGR of 6.5% to reach US$ 39,223.59 Million from 2020 to 2027
The Multiple Sclerosis Therapeutics Market was valued at US$ 24,026.90 million in 2019 and it is projected to reach US$ 39,223.59 million by 2027; it is expected to grow at a CAGR of 6.5% from 2020 to 2027.
Multiple sclerosis (MS) is an autoimmune disease affecting the central nervous system. The immune system attacks the nerves, which causes communication problems between the brain and rest of the body. Immunosuppressant and immunomodulators, along with physiotherapy, are widely used to treat MS.
The scope of the multiple sclerosis therapeutics market includes drug class, route of administration, distribution channel, and region. The market for multiple sclerosis therapeutics is analyzed based on regions such as North America, Europe, Asia Pacific, Middle East & Africa, and South and Central America. The report offers insights and in-depth analysis of the multiple sclerosis therapeutics market emphasizing on various parameters, such as market trends, technological advancements, market dynamics, and competitive landscape analysis of leading market players across the globe.
Customize Research To Suit Your Requirement
We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.
Multiple Sclerosis Therapeutics Market: Strategic Insights
Market Size Value in US$ 24,026.90 Million in 2019 Market Size Value by US$ 39,223.59 Million by 2027 Growth rate CAGR of 6.5% from 2020-2027 Forecast Period 2020-2027 Base Year 2020
Mrinal
Have a question?
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
Customize Research To Suit Your Requirement
We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.
Multiple Sclerosis Therapeutics Market: Strategic Insights
| Market Size Value in | US$ 24,026.90 Million in 2019 |
| Market Size Value by | US$ 39,223.59 Million by 2027 |
| Growth rate | CAGR of 6.5% from 2020-2027 |
| Forecast Period | 2020-2027 |
| Base Year | 2020 |
Mrinal
Have a question?
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
Market Insights
Growing Prevalence of Multiple Sclerosis
Multiple sclerosis is a chronic disease that affects the brain, spinal cord, and optic nerves. The symptoms of multiple sclerosis include weakness, anxiety, abnormality of taste, reduced sensation, and blurred vision or vision loss. Some of the other signs are constipation, muscle stiffness, depression, thinking problems, and urinary problems.
Studies suggest that there is an increase in prevalence of multiple sclerosis across the globe. For instance, as per the National Multiple Sclerosis Society’s study in 2017, about 1 million adults (up to 913,925) were living with MS in the US. In 2010, estimated prevalence of the disease was 309 cases per 100,000 people, that is, there were 727,344 adults suffering from MS. Additionally, as per the Government of Canada, (2014–2015 estimates) over 77,000 Canadians are living with multiple sclerosis of which 3/4th are women.
Further, the Multiple Sclerosis Society estimated that about 110,000 people were suffering from the condition in the UK in 2018. It also mentioned that MS is more than twice prevalent in females than males. The number of new patients diagnosed per year is also increasing; it increased from 5,000 in 2017 to 6,700 in 2018.
Therefore, growing prevalence of multiple sclerosis is driving the multiple sclerosis therapeutics market.
Drug Class Based Insights
Based on multiple sclerosis therapeutics drug class, the multiple sclerosis therapeutics market is segmented into immunosuppressant and immunomodulators. In 2019, the immunomodulators segment accounted for larger share of the market. Growth of this segment is attributed to launch of new generic drugs and increase in adoption of immunomodulators in MS treatment. The immunosuppressant segment is likely to register higher CAGR during the forecast period.
Route of Administration Based Insights
In terms of route of administration, the multiple sclerosis therapeutics market is segmented into injectable and oral. The injectable segment held larger share of the market in 2019, and same segment is anticipated to register higher CAGR during the forecast period.
Distribution Channel Based Insights
Based on distribution channel, the multiple sclerosis therapeutics market is segmented into hospital pharmacies, retail pharmacies, and e-commerce. The hospital pharmacies segment held the largest share of the market in 2019, and the e-commerce segment is anticipated to register the highest CAGR in the market during the forecast period.
COVID-19 pandemic has become the most significant challenge across the world. This challenge will be frightening especially in developing countries across the globe as it will lead to reducing imports due to disruptions in global trade. Till date no definitive treatment against COVID 19 has been established. Patients with severe health conditions, such as neurological diseases and others; are witnessing delays in such chronic disease treatment. Supply chain disruptions associated with this pandemic situation will ultimately affect the sales of products for short period. However, the supply of MS drugs has been continuous in the pandemic as pharmacies are allowed to open during the lock down. Several companies are cutting their clinical trial activities and delaying product launches in response to the COVID-19 pandemic. For instance, Bristol-Myers Squibb delayed the launch of its multiple-sclerosis drug Zeposia (ozanimod) due to the outbreak of COVID-19 pandemic.
Product launches and expansion strategies are commonly adopted by companies to expand their footprint worldwide and meet the growing demand. These strategies are commonly adopted by the market players in order to expand its product portfolio.
The market players operating in the Multiple Sclerosis Therapeutics Market adopted the strategy of product innovation to cater to changing customer demand across the world, which also permits the players to maintain their brand name globally.
Multiple Sclerosis Therapeutics Market Report Scope
By Drug Class
- Immunosuppressant
- Immunomodulators
By Route of Administration
- Injectable
- Oral
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- E-Commerce
By Geography
- North America
- US
- Canada
- Mexico
- Europe
- France
- Germany
- Italy
- UK
- Spain
- Rest of Europe
- Asia Pacific (APAC)
- China
- India
- South Korea
- Japan
- Australia
- Rest of Asia Pacific
- Middle East & Africa (MEA)
- South Africa
- Saudi Arabia
- UAE
- Rest of Middle East & Africa
- South America (SAM)
- Brazil
- Argentina
- Rest of South America
Company Profiles
- Merck & Co., Inc.
- Novartis AG
- Bayer AG
- Sanofi
- Bristol-Myers Squibb Company
- Horizon Therapeutics plc.
- TEVA PHARMACEUTICAL INDUSTRIES LTD
- Takeda Pharmaceutical Company Limited
- F. HOFFMANN-LA ROCHE LTD.
- Biogen
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
Drug Class , Route of Administration , and Distribution Channel , and Geography
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
Argentina, Australia, Brazil, Canada, China, France, Germany, India, Italy, Japan, Mexico, RoAPAC, RoE, RoMEA, RoSCAM, Saudi Arabia, South Africa, South Korea, Spain, United Arab Emirates, United Kingdom, United States
1. Introduction
1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
1.3.1 Global Multiple Sclerosis Therapeutics Market – By Drug Class
1.3.2 Global Multiple Sclerosis Therapeutics Market – By Route Of Administration
1.3.3 Global Multiple Sclerosis Therapeutics Market – By Distribution Channel
1.3.4 Global Multiple Sclerosis Therapeutics Market – By Geography
2. Multiple Sclerosis Therapeutics Market – Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Global Multiple Sclerosis Therapeutics– Market Landscape
4.1 Overview
4.2 PEST Analysis
4.2.1 North America – PEST Analysis
4.2.2 Europe – PEST Analysis
4.2.3 Asia Pacific – PEST Analysis
4.2.4 Middle East and Africa (MEA) – PEST Analysis
4.2.5 South and Central America (SCAM) – PEST Analysis
4.1 Expert Opinions
5. Multiple Sclerosis Therapeutics Market – Key Market Dynamics
5.1 Market Drivers
5.1.1 Growing Prevalence of Multiple Sclerosis (MS)
5.1.2 Rising Funding for Multiple Sclerosis Research
5.2 Market Restraints
5.2.1 High Cost of Multiple Sclerosis Treatment
5.3 Market Opportunities
5.3.1 Increasing Awareness About Multiple Sclerosis
5.4 Future Trends
5.4.1 Development and Launch of Innovative Products
5.5 Impact analysis
6. Multiple Sclerosis Therapeutics Market – Global Analysis
6.1 Global Multiple Sclerosis Therapeutics Market Revenue Forecast And Analysis
6.2 Global Multiple Sclerosis Therapeutics Market, By Geography - Forecast And Analysis
6.3 Market Positioning of Key Players
7. Multiple Sclerosis Therapeutics Market Analysis – By Drug Class
7.1 Overview
7.2 Multiple Sclerosis Therapeutics Market Revenue Share, by Drug Class (2019 and 2027)
7.3 Immunosuppressant
7.3.1 Overview
7.3.2 Immunosuppressant: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)
7.4 Immunomodulators
7.4.1 Overview
7.4.2 Immunomodulators: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)
8. Multiple Sclerosis Therapeutics Market Analysis – By Route of Administration
8.1 Overview
8.2 Multiple Sclerosis Therapeutics Market Revenue Share, by Route of Administration (2019 and 2027)
8.3 Injectable
8.3.1 Overview
8.3.2 Injectable: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)
8.4 Oral
8.4.1 Overview
8.4.2 Oral: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)
9. Multiple Sclerosis Therapeutics Market Analysis – By Distribution Channel
9.1 Overview
9.2 Multiple Sclerosis Therapeutics Market Share, by Distribution Channel, 2019 and 2027
9.3 Hospital Pharmacies
9.3.1 Overview
9.3.2 Hospital Pharmacies: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)
9.4 Retail Pharmacies
9.4.1 Overview
9.4.2 Retail Pharmacies: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)
9.5 E-Commerce
9.5.1 Overview
9.5.2 E-Commerce: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)
10. Multiple Sclerosis Therapeutics Market Analysis And Forecast To 2027 – Geographical Analysis
10.1 North America: Multiple Sclerosis Therapeutics Market
10.1.1 Overview
10.1.2 North America: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (USD Million)
10.1.3 North America: Multiple Sclerosis Therapeutics Market, by Drug Class, 2018–2027 (USD Million)
10.1.4 North America: Multiple Sclerosis Therapeutics Market, by Route of Administration, 2018–2027 (USD Million)
10.1.5 North America: Multiple Sclerosis Therapeutics Market, by Distribution Channel, 2018–2027 (USD Million)
10.1.6 North America: Multiple Sclerosis Therapeutics Market, by Country, 2019 & 2027 (%)
10.1.7 US: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (USD Million)
10.1.7.1 US: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (USD Million)
10.1.7.2 US: Multiple Sclerosis Therapeutics Market, by Drug Class, 2018–2027 (USD Million)
10.1.7.3 US: Multiple Sclerosis Therapeutics Market, by Route of Administration 2018–2027 (USD Million)
10.1.7.4 US: Multiple Sclerosis Therapeutics Market, by Distribution Channel 2018–2027 (USD Million)
10.1.8 Canada: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (USD Million)
10.1.8.1 Canada: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (USD Million)
10.1.8.2 Canada: Multiple Sclerosis Therapeutics Market, by Drug Class, 2018–2027 (USD Million)
10.1.8.3 Canada: Multiple Sclerosis Therapeutics Market, by Route of Administration 2018–2027 (USD Million)
10.1.8.4 Canada: Multiple Sclerosis Therapeutics Market, by Distribution Channel 2018–2027 (USD Million)
10.1.9 Mexico: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (USD Million)
10.1.9.1 Mexico: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (USD Million)
10.1.9.2 Mexico: Multiple Sclerosis Therapeutics Market, by Drug Class, 2018–2027 (USD Million)
10.1.9.3 Mexico: Multiple Sclerosis Therapeutics Market, by Route of Administration 2018–2027 (USD Million)
10.1.9.4 Mexico: Multiple Sclerosis Therapeutics Market, by Distribution Channel, 2018–2027 (USD Million)
10.2 Europe: Multiple Sclerosis Therapeutics Market
10.2.1 Overview
10.2.2 Europe: Multiple Sclerosis Therapeutics Market - Revenue and Forecast to 2027 (USD Million)
10.2.3 Europe Multiple Sclerosis Therapeutics Market, by Drug Class – Revenue and Forecast to 2027 (USD Million)
10.2.4 Europe Multiple Sclerosis Therapeutics Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)
10.2.5 Europe Multiple Sclerosis Therapeutics Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million)
10.2.6 Europe: Multiple Sclerosis Therapeutics Market, by Country, 2019 & 2027 (%)
10.2.7 Germany: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (USD Million)
10.2.7.1 Germany: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (USD Million)
10.2.7.2 Germany Multiple Sclerosis Therapeutics Market, by Drug Class – Revenue and Forecast to 2027 (USD Million)
10.2.7.3 Germany Multiple Sclerosis Therapeutics Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)
10.2.7.4 Germany Multiple Sclerosis Therapeutics Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million)
10.2.8 UK: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (USD Million)
10.2.8.1 UK: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (USD Million)
10.2.8.2 UK Multiple Sclerosis Therapeutics Market, by Drug Class – Revenue and Forecast to 2027 (USD Million)
10.2.8.3 UK Multiple Sclerosis Therapeutics Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)
10.2.8.4 UK Multiple Sclerosis Therapeutics Market, by Distribution Channel– Revenue and Forecast to 2027 (USD Million)
10.2.9 France: Market – Revenue and Forecast to 2027 (USD Million)
10.2.9.1 France: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (USD Million)
10.2.9.2 France Multiple Sclerosis Therapeutics Market, by Drug Class – Revenue and Forecast to 2027 (USD Million)
10.2.9.3 France Multiple Sclerosis Therapeutics Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)
10.2.9.4 France Multiple Sclerosis Therapeutics Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million)
10.2.10 Spain: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (USD Million)
10.2.10.1 Spain: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (USD Million)
10.2.10.2 Spain Multiple Sclerosis Therapeutics Market, by Drug Class – Revenue and Forecast to 2027 (USD Million)
10.2.10.3 Spain Multiple Sclerosis Therapeutics Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)
10.2.10.4 Spain Multiple Sclerosis Therapeutics Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million)
10.2.11 Italy: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (USD Million)
10.2.11.1 Italy: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (USD Million)
10.2.11.2 Italy Multiple Sclerosis Therapeutics Market, by Drug Class – Revenue and Forecast to 2027 (USD Million)
10.2.11.3 Italy Multiple Sclerosis Therapeutics Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)
10.2.11.4 Italy Multiple Sclerosis Therapeutics Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million)
10.2.12 Rest of Europe: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (USD Million)
10.2.12.1 Rest of Europe: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (USD Million)
10.2.12.2 Rest of Europe Multiple Sclerosis Therapeutics Market, by Drug Class – Revenue and Forecast to 2027 (USD Million)
10.2.12.3 Rest of Europe Multiple Sclerosis Therapeutics Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)
10.2.12.4 Rest of Europe Multiple Sclerosis Therapeutics Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million)
10.3 Asia Pacific Multiple Sclerosis Therapeutics Market Revenue And Forecasts To 2027
10.3.1 Overview
10.3.2 Asia Pacific Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027 (US$ Mn)
10.3.3 Asia Pacific Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027, By Drug Class (US$ Mn)
10.3.4 Asia Pacific Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027, By Route of Administration (US$ Mn)
10.3.5 Asia Pacific Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027, By Distribution Channel (US$ Mn)
10.3.6 Asia Pacific Multiple Sclerosis Therapeutics Market share, By Country (2019 & 2027) (%)
10.3.7 China Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027 (US$ Mn)
10.3.7.1 China Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027 (US$ Mn)
10.3.7.2 China Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027, By Drug Class (US$ Mn)
10.3.7.3 China Multiple Sclerosis Therapeutics Market Revenue And Forecasts To 2027, By Route of Administration (US$ Mn)
10.3.7.4 China Multiple Sclerosis Therapeutics Market Revenue And Forecasts To 2027, By Distribution Channel (US$ Mn)
10.3.8 Japan Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027 (US$ Mn)
10.3.8.1 Japan Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027 (US$ Mn)
10.3.8.2 Japan Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027, By Drug Class (US$ Mn)
10.3.8.3 Japan Multiple Sclerosis Therapeutics Market Revenue And Forecasts To 2027, By Route of Administration (US$ Mn)
10.3.8.4 Japan Multiple Sclerosis Therapeutics Market Revenue And Forecasts To 2027, By Distribution Channel (US$ Mn)
10.3.9 India Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027 (US$ Mn)
10.3.9.1 India Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027 (US$ Mn)
10.3.9.2 India Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027, By Drug Class (US$ Mn)
10.3.9.3 India Multiple Sclerosis Therapeutics Market Revenue And Forecasts To 2027, By Route of Administration (US$ Mn)
10.3.9.4 India Multiple Sclerosis Therapeutics Market Revenue And Forecasts To 2027, By Distribution Channel (US$ Mn)
10.3.10 South Korea Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027 (US$ Mn)
10.3.10.1 South Korea Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027 (US$ Mn)
10.3.10.2 South Korea Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027, By Drug Class (US$ Mn)
10.3.10.3 South Korea Multiple Sclerosis Therapeutics Market Revenue And Forecasts To 2027, By Distribution Channel (US$ Mn)
10.3.10.4 South Korea Multiple Sclerosis Therapeutics Market Revenue And Forecasts To 2027, By Distribution Channel (US$ Mn)
10.3.11 Australia Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027 (US$ Mn)
10.3.11.1 Australia Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027 (US$ Mn)
10.3.11.2 Australia Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027, By Drug Class (US$ Mn)
10.3.11.3 Australia Multiple Sclerosis Therapeutics Market Revenue And Forecasts To 2027, By Route of Administration (US$ Mn)
10.3.11.4 Australia Multiple Sclerosis Therapeutics Market Revenue And Forecasts To 2027, By Distribution Channel (US$ Mn)
10.3.12 Rest of Asia Pacific: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (USD Million)
10.4 Middle East & Africa Multiple Sclerosis Therapeutics Market Revenue And Forecasts To 2027
10.4.1 Overview
10.4.2 Middle East And Africa Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027 (US$ Mn)
10.4.3 Middle East And Africa Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027, By Drug Class (US$ Mn)
10.4.4 Middle East And Africa Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027, By Route of Administration (US$ Mn)
10.4.5 Middle East And Africa Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027, By Distribution Channel (US$ Mn)
10.4.6 Middle East And Africa Multiple Sclerosis Therapeutics Market Share, By Country (2019 & 2027) (%)
10.4.7 Saudi Arabia Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027 (US$ Mn)
10.4.7.1 Saudi Arabia Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027 (US$ Mn)
10.4.7.2 Saudi Arabia Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027, By Drug Class (US$ Mn)
10.4.7.3 Saudi Arabia Multiple Sclerosis Therapeutics Market Revenue And Forecasts To 2027, By Route of Administration (US$ Mn)
10.4.7.4 Saudi Arabia Multiple Sclerosis Therapeutics Market Revenue And Forecasts To 2027, By Distribution Channel (US$ Mn)
10.4.8 South Africa Multiple Sclerosis Therapeutics Market Revenue And Forecasts To 2027
10.4.8.1 South Africa Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027 (US$ Mn)
10.4.8.2 South Africa Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027, By Drug Class (US$ Mn)
10.4.8.3 South Africa Multiple Sclerosis Therapeutics Market Revenue And Forecasts To 2027, By Route of Administration (US$ Mn)
10.4.8.4 South Africa Multiple Sclerosis Therapeutics Market Revenue And Forecasts To 2027, By Distribution Channel US$ Mn)
10.4.9 UAE Multiple Sclerosis Therapeutics Market Revenue And Forecasts To 2027
10.4.9.1 UAE Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027 (US$ Mn)
10.4.9.2 UAE Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027, By Drug Class (US$ Mn)
10.4.9.3 UAE Multiple Sclerosis Therapeutics Market Revenue And Forecasts To 2027, By Route of Administration (US$ Mn)
10.4.9.4 UAE Multiple Sclerosis Therapeutics Market Revenue And Forecasts To 2027, By Distribution Channel (US$ Mn)
10.4.9.5 Rest of Middle East and Africa: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (USD Million)
10.5 South and Central America: Multiple Sclerosis Therapeutics Market
10.5.1 Overview
10.5.2 South and Central America: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (USD Million)
10.5.3 South and Central America: Multiple Sclerosis Therapeutics Market, by Drug Class, 2018–2027 (USD Million)
10.5.4 South and Central America: Multiple Sclerosis Therapeutics Market, by Route of Administration 2018–2027 (USD Million)
10.5.5 South and Central America: Multiple Sclerosis Therapeutics Market, by Distribution Channel, 2018–2027 (USD Million)
10.5.6 South and Central America: Multiple Sclerosis Therapeutics Market, by Country, 2019 & 2027 (%)
10.5.7 Brazil: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (USD Million)
10.5.7.1 Brazil: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (USD Million)
10.5.7.2 Brazil: Multiple Sclerosis Therapeutics Market, by Drug Class, 2018–2027 (USD Million)
10.5.7.3 Brazil: Multiple Sclerosis Therapeutics Market, by Route of Administration 2018–2027 (USD Million)
10.5.7.4 Brazil: Multiple Sclerosis Therapeutics Market, by Distribution Channel, 2018–2027 (USD Million)
10.5.8 Argentina: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (USD Million)
10.5.8.1 Argentina: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (USD Million)
10.5.8.2 Argentina: Multiple Sclerosis Therapeutics Market, by Drug Class, 2018–2027 (USD Million)
10.5.8.3 Argentina: Multiple Sclerosis Therapeutics Market, by Route of Administration 2018–2027 (USD Million)
10.5.8.4 Argentina: Multiple Sclerosis Therapeutics Market, by Distribution Channel, 2018–2027 (USD Million)
10.5.9 Rest of South and Central America: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (USD Million)
10.5.9.1 Rest of South and Central America: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (USD Million)
10.5.9.2 Rest of South and Central America: Multiple Sclerosis Therapeutics Market, by Drug Class, 2018–2027 (USD Million)
10.5.9.3 Rest of South and Central America: Multiple Sclerosis Therapeutics Market, by Route of Administration 2018–2027 (USD Million)
10.5.9.4 Rest of South and Central America: Multiple Sclerosis Therapeutics Market, by Distribution Channel, 2018–2027 (USD Million)
11. Impact of COVID-19 Pandemic on Global Multiple Sclerosis Therapeutics Market
11.1 North America: Impact Assessment of COVID-19 Pandemic
11.2 Europe: Impact Assessment Of COVID-19 Pandemic
11.3 Asia-Pacific: Impact Assessment of COVID-19 Pandemic
11.4 Middle East & Africa: Impact Assessment of COVID-19 Pandemic
11.5 South & Central America: Impact Assessment of COVID-19 Pandemic
12. Industry Landscape
12.1 Overview
12.2 Growth Strategies Done by the Companies in the Market, (%)
12.3 Organic Developments
12.3.1 Overview
12.4 Inorganic Developments
12.4.1 Overview
13. Company Profiles
13.1 Merck & Co., Inc.
13.1.1 Key Facts
13.1.2 Business Description
13.1.3 Products and Services
13.1.4 Financial Overview
13.1.5 SWOT Analysis
13.1.6 Key Developments
13.2 Novartis AG
13.2.1 Key Facts
13.2.2 Business Description
13.2.3 Products and Services
13.2.4 Financial Overview
13.2.5 SWOT Analysis
13.2.6 Key Developments
13.3 Bayer AG
13.3.1 Key Facts
13.3.2 Business Description
13.3.3 Products and Services
13.3.4 Financial Overview
13.3.5 SWOT Analysis
13.3.6 Key Developments
13.4 Sanofi
13.4.1 Key Facts
13.4.2 Business Description
13.4.3 Products and Services
13.4.4 Financial Overview
13.4.5 SWOT Analysis
13.4.6 Key Developments
13.5 Bristol-Myers Squibb Company
13.5.1 Key Facts
13.5.2 Business Description
13.5.3 Products and Services
13.5.4 Financial Overview
13.5.5 SWOT Analysis
13.5.6 Key Developments
13.6 Horizon Therapeutics plc
13.6.1 Key Facts
13.6.2 Business Description
13.6.3 Products and Services
13.6.4 Financial Overview
13.6.5 SWOT Analysis
13.6.6 Key Developments
13.7 TEVA PHARMACEUTICAL INDUSTRIES LTD
13.7.1 Key Facts
13.7.2 Business Description
13.7.3 Products and Services
13.7.4 Financial Overview
13.7.5 SWOT Analysis
13.7.6 Key Developments
13.8 Takeda Pharmaceutical Company Limited
13.8.1 Key Facts
13.8.2 Business Description
13.8.3 Products and Services
13.8.4 Financial Overview
13.8.5 SWOT Analysis
13.8.6 Key Developments
13.9 F. HOFFMANN-LA ROCHE LTD.
13.9.1 Key Facts
13.9.2 Business Description
13.9.3 Products and Services
13.9.4 Financial Overview
13.9.5 SWOT Analysis
13.9.6 Key Developments
13.10 Biogen
13.10.1 Key Facts
13.10.2 Business Description
13.10.3 Products and Services
13.10.4 Financial Overview
13.10.5 SWOT Analysis
13.10.6 Key Developments
14. Appendix
14.1 About The Insight Partners
14.2 Glossary of Terms
LIST OF TABLES
Table 1. North America Multiple Sclerosis Therapeutics Market, by Drug Class – Revenue and Forecast to 2027 (USD Million)
Table 2. North America Multiple Sclerosis Therapeutics Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)
Table 3. North America Multiple Sclerosis Therapeutics Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million)
Table 4. US Multiple Sclerosis Therapeutics Market, by Drug Class – Revenue and Forecast to 2027 (USD Million)
Table 5. US Multiple Sclerosis Therapeutics Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)
Table 6. US Multiple Sclerosis Therapeutics Market, by Distribution Channel– Revenue and Forecast to 2027 (USD Million)
Table 7. Canada Multiple Sclerosis Therapeutics Market, by Drug Class – Revenue and Forecast to 2027 (USD Million)
Table 8. Canada Multiple Sclerosis Therapeutics Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)
Table 9. Canada Multiple Sclerosis Therapeutics Market, by Distribution Channel– Revenue and Forecast to 2027 (USD Million)
Table 10. Mexico Multiple Sclerosis Therapeutics Market, by Drug Class – Revenue and Forecast to 2027 (USD Million)
Table 11. Mexico Multiple Sclerosis Therapeutics Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)
Table 12. Mexico Multiple Sclerosis Therapeutics Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million)
Table 13. Europe Multiple Sclerosis Therapeutics Market, by Drug Class – Revenue and Forecast to 2027 (USD Million)
Table 14. Europe Multiple Sclerosis Therapeutics Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)
Table 15. Europe Multiple Sclerosis Therapeutics Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million)
Table 16. Germany Multiple Sclerosis Therapeutics Market, by Drug Class – Revenue and Forecast to 2027 (USD Million)
Table 17. Germany Multiple Sclerosis Therapeutics Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)
Table 18. Germany Multiple Sclerosis Therapeutics Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million)
Table 19. UK Multiple Sclerosis Therapeutics Market, by Drug Class – Revenue and Forecast to 2027 (USD Million)
Table 20. UK Multiple Sclerosis Therapeutics Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)
Table 21. UK: Multiple Sclerosis Therapeutics Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million).
Table 22. France Multiple Sclerosis Therapeutics Market, by Drug Class – Revenue and Forecast to 2027 (USD Million)
Table 23. France Multiple Sclerosis Therapeutics Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)
Table 24. France Multiple Sclerosis Therapeutics Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million)
Table 25. Spain Multiple Sclerosis Therapeutics Market, by Drug Class – Revenue and Forecast to 2027 (USD Million)
Table 26. Spain Multiple Sclerosis Therapeutics Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)
Table 27. Spain Multiple Sclerosis Therapeutics Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million)
Table 28. Italy Multiple Sclerosis Therapeutics Market, by Drug Class – Revenue and Forecast to 2027 (USD Million)
Table 29. Italy Multiple Sclerosis Therapeutics Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)
Table 30. Italy Multiple Sclerosis Therapeutics Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million)
Table 31. Rest of Europe Multiple Sclerosis Therapeutics Market, by Drug Class – Revenue and Forecast to 2027 (USD Million)
Table 32. Rest of Europe Multiple Sclerosis Therapeutics Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)
Table 33. Rest of Europe Multiple Sclerosis Therapeutics Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million)
Table 34. Asia Pacific Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027, By Drug Class (US$ Mn)
Table 35. Asia Pacific Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027, By Route of Administration (US$ Mn)
Table 36. Asia Pacific Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027, By Distribution Channel (US$ Mn)
Table 37. China Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027, By Drug Class (US$ Mn)
Table 38. China Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027, By Route of Administration (US$ Mn)
Table 39. China Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027, By Distribution Channel (US$ Mn)
Table 40. Japan Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027, By Drug Class (US$ Mn)
Table 41. Japan Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027, By Route of Administration (US$ Mn)
Table 42. Japan Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027, By Distribution Channel (US$ Mn)
Table 43. India Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027, By Drug Class (US$ Mn)
Table 44. India Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027, By Route of Administration (US$ Mn)
Table 45. India Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027, By Distribution Channel (US$ Mn)
Table 46. South Korea Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027, By Drug Class (US$ Mn)
Table 47. South Korea Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027, By Distribution Channel (US$ Mn)
Table 48. South Korea Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027, By Distribution Channel (US$ Mn)
Table 49. Australia Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027, By Drug Class (US$ Mn)
Table 50. Australia Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027, By Route of Administration (US$ Mn)
Table 51. Australia Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027, By Distribution Channel (US$ Mn)
Table 55. Middle East And Africa Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027, By Drug Class (US$ Mn)
Table 56. Middle East And Africa Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027, By Route of Administration (US$ Mn)
Table 57. Middle East And Africa Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027, By Route of Administration (US$ Mn)
Table 58. Saudi Arabia Multiple Sclerosis Therapeutic market Revenue And Forecasts to 2027, By Drug Class (US$ Mn)
Table 59. Saudi Arabia Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027, By Route of Administration (US$ Mn)
Table 60. Saudi Arabia Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027, By Distribution Channel (US$ Mn)
Table 61. South Africa Multiple Sclerosis Therapeutic market Revenue And Forecasts to 2027, By Drug Class (US$ Mn)
Table 62. South Africa Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027, By Route of Administration (US$ Mn)
Table 63. South Africa Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027, By Distribution Channel (US$ Mn)
Table 64. UAE Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027, By Drug Class (US$ Mn)
Table 65. UAE Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027, By Route of Administration (US$ Mn)
Table 66. UAE Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027, By Distribution Channel (US$ Mn)
Table 70. South and Central America Multiple Sclerosis Therapeutics Market, by Drug Class – Revenue and Forecast to 2027 (USD Million)
Table 71. South and Central America Multiple Sclerosis Therapeutics Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)
Table 72. South and Central America Multiple Sclerosis Therapeutics Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million)
Table 73. Brazil Multiple Sclerosis Therapeutics Market, by Drug Class – Revenue and Forecast to 2027 (USD Million)
Table 74. Brazil Multiple Sclerosis Therapeutics Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)
Table 75. Brazil Multiple Sclerosis Therapeutics Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million)
Table 76. Argentina Multiple Sclerosis Therapeutics Market, by Drug Class – Revenue and Forecast to 2027 (USD Million)
Table 77. Argentina Multiple Sclerosis Therapeutics Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)
Table 78. Argentina Multiple Sclerosis Therapeutics Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million)
Table 79. Rest of South and Central America Multiple Sclerosis Therapeutics Market, by Drug Class – Revenue and Forecast to 2027 (USD Million)
Table 80. Rest of South and Central America Multiple Sclerosis Therapeutics Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)
Table 81. Rest of South and Central America Multiple Sclerosis Therapeutics Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million)
Table 82. Organic Developments Done By Companies
Table 83. Inorganic Developments Done By Companies
Table 84. Glossary of Terms, Multiple sclerosis therapeutics Market
LIST OF FIGURES
Figure 1. Multiple Sclerosis Therapeutics Market Segmentation
Figure 2. Multiple Sclerosis Therapeutics Market Segmentation, By Region
Figure 3. Multiple Sclerosis Therapeutics Market Overview
Figure 4. Immunomodulators Segment by Drug Class Held the Larger Share
Figure 5. APAC to Show Significant Growth During Forecast Period
Figure 6. Multiple Sclerosis Therapeutics Market, by Geography (US$ Million)
Figure 7. Global Multiple Sclerosis Therapeutics Market – Leading Country Markets (US$ Million)
Figure 8. Global Multiple Sclerosis Therapeutics Market, Industry Landscape
Figure 9. North America PEST Analysis
Figure 10. Europe PEST Analysis
Figure 11. Asia Pacific PEST Analysis
Figure 12. Middle East and Africa (MEA) PEST Analysis
Figure 13. South and Central America (SCAM) PEST Analysis
Figure 14. Multiple Sclerosis Therapeutics Market Impact Analysis of Driver and Restraints
Figure 15. Global Multiple Sclerosis Therapeutics Market – Revenue Forecast And Analysis – 2019- 2027
Figure 16. Global Multiple Sclerosis Therapeutics Market – By Geography Forecast and Analysis – 2019- 2027
Figure 17. Market Positioning Of Key Players In Global Multiple Sclerosis Therapeutics Market
Figure 18. Multiple Sclerosis Therapeutics Market Revenue Share, by Drug Class (2019 and 2027)
Figure 19. Immunosuppressant: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)
Figure 20. Immunomodulators: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)
Figure 21. Multiple Sclerosis Therapeutics Market Revenue Share, by Route of Administration (2019 and 2027)
Figure 22. Injectable: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)
Figure 23. Oral: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)
Figure 24. Multiple Sclerosis Therapeutics Market Share, by Distribution Channel, 2019 and 2027
Figure 25. Hospital Pharmacies: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)
Figure 26. Retail Pharmacies: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)
Figure 27. E-Commerce: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)
Figure 28. North America: Multiple Sclerosis Therapeutics Market, by Key Country – Revenue (2019) (USD Million)
Figure 29. North America Multiple Sclerosis Therapeutics Market Revenue and Forecast to 2027 (USD Million)
Figure 30. North America: Multiple Sclerosis Therapeutics Market, by Country, 2019 & 2027 (%)
Figure 31. US: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (USD Million)
Figure 32. Canada: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (USD Million)
Figure 33. Mexico: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (USD Million)
Figure 34. Europe: Multiple Sclerosis Therapeutics Market, by Key Country – Revenue (2019) (USD Million)
Figure 35. Europe Multiple Sclerosis Therapeutics Market Revenue and Forecast to 2027 (USD Million)
Figure 36. Europe: Multiple Sclerosis Therapeutics Market, by Country, 2019 & 2027 (%)
Figure 37. Germany: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (USD Million)
Figure 38. UK: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (USD Million)
Figure 39. France: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (USD Million)
Figure 40. Spain: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (USD Million)
Figure 41. Italy: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (USD Million)
Figure 42. Rest of Europe: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (USD Million)
Figure 43. Asia Pacific Multiple Sclerosis Therapeutics Market Overview, by Country (2019)
Figure 44. Asia Pacific Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027 (US$ Mn)
Figure 45. Asia Pacific Multiple Sclerosis Therapeutics Market share, By Country (2019 & 2027) (%)
Figure 46. China Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027 (US$ Mn)
Figure 47. Japan Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027 (US$ Mn)
Figure 48. India Multiple Sclerosis Therapeutic market Revenue And Forecasts to 2027 (US$ Mn)
Figure 49. South Korea Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027 (US$ Mn)
Figure 50. Australia Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027 (US$ Mn)
Figure 52. Middle East & Africa Multiple Sclerosis Therapeutics Market Share Overview, By Country (2019)
Figure 53. Middle East And Africa Multiple Sclerosis Therapeutic market Revenue And Forecasts to 2027 (US$ Mn)
Figure 54. Middle East And Africa Multiple Sclerosis Therapeutics Market Share, By Country (2019 & 2027) (%)
Figure 55. Saudi Arabia Multiple Sclerosis Therapeutic market Revenue And Forecasts to 2027 (US$ Mn)
Figure 56. South Africa Multiple Sclerosis Therapeutic market Revenue And Forecasts to 2027 (US$ Mn)
Figure 57. UAE Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027 (US$ Mn)
Figure 59. South and Central America: Multiple Sclerosis Therapeutics Market, by Key Country – Revenue (2019) (USD Million)
Figure 60. South and Central America Multiple Sclerosis Therapeutics Market Revenue and Forecast to 2027 (USD Million)
Figure 61. South and Central America: Multiple Sclerosis Therapeutics Market, by Country, 2019 & 2027 (%)
Figure 62. Brazil: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (USD Million)
Figure 63. Argentina: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (USD Million)
Figure 64. Rest of South and Central America: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (USD Million)
Figure 65. Impact of COVID-19 Pandemic in North American Country Markets
Figure 66. Impact of COVID-19 Pandemic in European Country Markets
Figure 67. Impact of COVID-19 Pandemic in Asia Pacific Country Markets
Figure 68. Impact of COVID-19 Pandemic in Middle East & Africa Market
Figure 69. Impact of COVID-19 Pandemic in South & Central America Market
Figure 70. Growth Strategies Done by the Companies in the Market, (%)
The List of Companies - Multiple Sclerosis Therapeutics Market
- Merck & Co., Inc.
- Novartis AG
- Bayer AG
- Sanofi
- Bristol-Myers Squibb Company
- Horizon Therapeutics plc.
- TEVA PHARMACEUTICAL INDUSTRIES LTD
- Takeda Pharmaceutical Company Limited
- F. HOFFMANN-LA ROCHE LTD.
- Biogen
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- 3.1 Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- 3.2 Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- 3.3 Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- 3.4 Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Get Free Sample For